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Abstract
Vitamin K prophylaxis in infancy aims to prevent life-threatening vitamin K deficiency bleeding (VKDB). The Dutch prophy-
lactic oral daily regimen was increased sixfold from 25 to 150 μg because of a high failure rate. To evaluate the efficacy of this
new regimen, incidences of intracranial VKDB under both regimens were compared using both general and targeted surveillance.
Late VKDB in the general pediatric population was identified by the Netherlands Pediatric Surveillance Unit, between 1 October
2014 and 31 December 2016. Additionally, infants with intracranial vitamin K deficiency bleeding were identified using the
Dutch Pediatric Intensive Care Evaluation registry. The incidence of intracranial VKDB as assessed by general and targeted
surveillance decreased from 1.6 per 100,000 (95% CI, 0.4–5.1) to 1.3 per 100,000 (95% CI, 0.5–3.2) and from 3.1 per 100,000
live births (95% CI, 1.9–5.0) to 1.2 per 100,000 live births (95% CI, 0.6–2.3), respectively. Median time between consecutive
cases in the latter increased from 24 to 154 days (p < 0.001).
Conclusion: A sixfold increase in oral vitamin K prophylaxis was associated with a surprisingly modest reduction in the
incidence of intracranial VKDB, indicating that factors other than the dose need addressing to improve efficacy.
What is Known:
• The efficacy of intramuscular vitamin K prophylaxis is threatened by an increasing number of parents opting out.
• Oral prophylaxis represents an attractive and less invasive alternative but is inferior, especially in infants with malabsorption of vitamin K due to cholestasis.
What is New:
• Increasing the daily oral dose of vitamin K sixfold had a surprisingly modest effect on the incidence of late vitamin K deficiency bleeding.
• This finding indicates that factors other than the dose must play an important role.
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IM Intramuscular
NABI Non-accidental brain injury
NSCK Netherlands Pediatric Surveillance Unit
PFIC Progressive familial intrahepatic cholestasis
PICE Pediatric Intensive Care Evaluation
PICU Pediatric intensive care unit
PIM2 Pediatric Index of Mortality 2
PIVKAs Proteins induced in vitamin K absence
PT Prothrombin time
VKD Vitamin K deficiency
VKDB Vitamin K deficiency bleeding
Introduction
Vitamin K prophylaxis in infancy aims to reduce the risk of
vitamin K deficiency bleeding (VKDB), the consequences of
which are potentially lethal [14]. Most countries have imple-
mented vitamin K prophylactic regimens, but the route of
administration, the dose, the dosing frequency, and the vita-
min K formulation differ widely among regimens. The molec-
ular form of vitamin K currently used in the Netherlands and
nearly all countries for intramuscular (IM) and oral vitamin K
prophylaxis is phylloquinone (vitamin K1). The efficacy of a
single dose of 1 mg IM vitamin K1 is firmly established and is
associated with a low risk of VKDB of < 0.2/100,000 new-
borns [12]. However, its efficacy at a population level is cur-
rently threatened by an increasing number of parents opting
out [9, 10, 15, 16, 28]. On the other hand, a single dose of oral
vitamin K1 prophylaxis—while as effective in preventing
classical VKDB—is associated with a much higher risk of late
VKDB (roughly 4–7/100,000) [27], which is predominantly
manifested by intracranial hemorrhage [20].
The vast majority of prophylactic failures occur in
breastfed infants with malabsorption of vitamin K, mostly
due to cholestasis [17]. Unfortunately, malabsorption often
only becomes apparent after bleeding has occurred. A prophy-
lactic regimen should therefore allow protection for all infants,
including those with unrecognized cholestatic liver disease.
By using targeted surveillance of infants with biliary atre-
sia, it was previously shown that a weekly oral dose of 1 mg
vitamin K offered a protection similar to IM administration in
infants with cholestasis [23]. In contrast, a daily dose of 25 μg
(0.175 mg weekly) was associated with a much higher risk in
breastfed infants with biliary atresia and a much higher inci-
dence of late VKDB of ~ 2.1 per 100,000 [23, 25]. To address
this, the Dutch prophylactic dose was increased sixfold, from
25 daily to 150 μg daily (1.050 mg weekly) for all breastfed
infants in February 2011 [4].
A recent study in patients with biliary atresia questioned
the efficacy of this new regimen and suggested that the risk
had remained unchanged [29]. The aim of this study is to
determine the consequences of a sixfold increase in the oral
prophylactic vitamin K dose (150 μg) on the overall incidence
of late VKDB and late intracranial VKDB in the Netherlands
in comparison with the former oral prophylactic dose of
25 μg.
Materials and methods
General surveillance
From 1 October 2014 to 31 December 2016, the Netherlands
Pediatric Surveillance Unit (NSCK) of the Dutch Association
for Pediatrics performed a nationwide active surveillance fo-
cused on the identification of infants with late VKDB.
Patient selection
Pediatricians were asked to report all infants in whom bleed-
ing may have resulted from VKDB. Reported cases were con-
firmed as described previously [6]. Briefly, validation was
performed using a questionnaire asking for information about
the infant, feeding type, clinical presentation, dose and route
of vitamin K prophylaxis, associated diseases, laboratory data,
and outcome. Confirmed VKDB was diagnosed when pro-
thrombin time (PT) was ≥ 4 times the control value and at
least one of the following was present:
1. Platelet count normal or raised in combination with nor-
mal fibrinogen values
2. Prothrombin assay returned to normal after vitamin K
administration
3. Concentration of PIVKAs (proteins induced in vitamin K
absence) exceeding the normal controls [6]
Incidence of late (intracranial) VKDB
The incidence of late VKDB and late intracranial VKDB in
the general pediatric population under the 150 μg regimen
was calculated using these data (2014–2016) and was com-
pared with the incidence under the 25 μg regimen by the
NSCK in 2005 [6, 25].
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Targeted surveillance
Infants with late intracranial VKDB were identified by using
the Dutch Pediatric Intensive Care Evaluation (PICE) registry
between 1 January 2008 and 31 December 2015. The diagno-
ses of all infants admitted to the eight Dutch pediatric inten-
sive care units (PICUs) are registered in this national registry
from 2003 onward.
Patient selection
All infants between the age of 8 days and 6 months who were
admitted to a Dutch PICU with intracranial bleeding were iden-
tified in the PICE registry using the same procedure as previously
described [25]. Briefly, the search strategy included search items
that allowed detection through the diagnosis intracranial bleed-
ing, through the symptoms of intracranial bleeding and
through the underlying disorder. Search items were
“brain dead,” “cerebral infarct or stroke,” “intracranial
hemorrhage,” “convulsions,” “meningitis,” “gastro-intes-
tinal bleeding,” “hepatitis,” “other liver diseases,” “bili-
ary atresia,” “neonatal jaundice,” “other gastro-intestinal
diseases,” and “coagulation defects” [25]. In case a cen-
ter had not yet completed its PICE registration during
the study period, an analogous in-house search was per-
formed. Medical records of all selected patients were
reviewed to identify infants with intracranial bleeding.
Discharge letters and laboratory results were used to
confirm vitamin K deficiency (VKD) as the cause of
bleeding. Also, relevant clinical characteristics were ob-
tained. Late intracranial VKDB was defined as intracra-
nial bleeding confirmed by magnetic resonance imaging
or computer tomography, in combination with a PT of
≥ 4 times the control value which normalized after vita-
min K administration and/or a raised concentration of
PIVKAs. A raised concentration of PIVKAs was de-
fined as exceeding the normal controls [20]. Cases of
“highly probable” intracranial bleeding, in combination
with the above, were also considered to be late intracra-
nial VKDB. Cases who were diagnosed with VKD be-
fore bleeding occurred were considered to be treatment
failures.
Clinical characteristics
Infants with late intracranial VKDBwere categorized into two
groups according to the type of prophylaxis (25 μg vs.
150 μg). Vitamin K prophylaxis was considered to be given
as recommended by the Dutch guideline at that time (1 mg at
birth and 25 μg or 150 μg daily until the age of 3 months)
unless otherwise specified. As the regimen was changed in
February 2011, all patients with late intracranial VKDB who
were born after February 2011 were considered to be 150-μg
regimen cases. Age at diagnosis was defined as the age of the
infant when first seen by a doctor with VKD-related
symptoms.
Infants were classified as “exclusively breastfed” if they
had received exclusively breastmilk from birth onward.
Adequate vitamin K administration was defined as adminis-
tration ≥ 5 times a week. Cholestasis was defined as a
concentration of total serum bilirubin ≥ 50 μmol/l with a
direct fraction of ≥ 20% [23]. Since the risk of VKDB
is not correlated with the degree of conjugated
hyperbilirubinemia [24], we also retrieved and described
the total and conjugated bilirubin levels. To compare the
severity of VKDB under the different regimens, the fol-
lowing parameters were determined: the Pediatric Index
of Mortality 2 (PIM2) score, which can be used for
comparison of risk-adjusted mortality among infants ad-
mitted to a PICU [18]; mechanical ventilation; length of
stay at a PICU; neurosurgical intervention; occurrence
of neurological sequelae; and mortality.
Incidence of late intracranial VKDB
The incidence of late intracranial VKDB between 2008 and
2015 was calculated using the number of live births for each
year [1, 2].
Efficacy of the revised regimen
To evaluate the efficacy of the revised regimen, the time be-
tween events (median time between consecutive cases) under
both regimens was compared, which is inversely related to the
incidence. Additionally, we performed a sensitivity anal-
ysis by calculating the adjusted incidence of late intra-
cranial VKDB, excluding infants who had received in-
adequate prophylaxis and infants that had not been ex-
clusively breastfed. Approval for the study was obtained
from the Medical Ethical Committee of the University
Medical Center Utrecht.
Statistical analysis
Clinical and biochemical data were analyzed using a t test in
case of a normal distribution and a Mann-Whitney U test for
parameters with a non-normal distribution. A Pearson chi-
squared test or Fisher’s exact test was used to determine sta-
tistical significance between groups in case of dichotomous
parameters. A p value < 0.05 was considered statistically sig-
nificant. SPSS (version 22.0; IBM Corp, Armonk, NY) was
used for all analyses. The 95% confidence intervals for the
incidences were calculated with R (version 3.3.65126.0_3-0)
(supplementary information).
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Results
General surveillance
Between 1 October 2014 and 31 December 2016, 10 cases
with suspected late VKDB were reported to the NSCK. Of
these, 1 infant was excluded from analysis because the
prolonged coagulation time did not cause a bleeding. Of the
remaining 9 cases, late intracranial VKDBwas confirmed in 5
infants and suspected in 1 infant in whom PT was measured
after parenteral administration of vitamin K. In the remaining
3 infants, bleeding occurred but at a different site (Table 1).
One of these infants did not receive vitamin K administration
and was therefore excluded from analysis. Under the 150-μg
regimen, the incidence of confirmed late VKDB was 1.8 per
100,000 (95% CI, 0.8–3.9), more than 70% of which were
intracranial bleedings, accumulating to an incidence of con-
firmed late intracranial VKDB of 1.3 per 100,000 (95% CI,
0.5–3.2). These incidences were lower than those obtained by
the NSCK in 2005 under the 25-μg regimen: 3.2 per 100,000
(95% CI, 1.2–6.9) and 1.6 per 100,000 (95% CI, 0.4–5.1),
respectively [6]. However, there are overlapping confidence
intervals.
Targeted surveillance
Between 1 January 2008 and 31 December 2015, a total of
45,063 patients were admitted to the eight Dutch PICUs. Of
these, 175 infants were diagnosed with intracranial bleeding.
Proven or highly suspected non-accidental brain injury
(NABI) represented the main cause (73 patients, 42%),
followed by accidental head trauma (45 patients, 26%). Late
intracranial VKDB was confirmed in 28 infants (16%).
Patients with late intracranial VKDB presented significantly
earlier than patients with intracranial bleeding due to NABI
(50 days vs. 85 days, respectively, p < 0.001). In addition,
Table 1 All registered cases of late VKDB in the Netherlands by general surveillance between October 2014 and December 2016
Sex; age
(days)
Vitamin K prophylaxis Clinical presentation Late intracranial
VKDB
Type of
feeding
APTT(s)/
PT(s)/
INR
Underlying
disorder
Outcome
M; 22 1 mg postpartum,
150 μg/day per os
Intracranial bleeding Yes BF > 200/
> 180/
NM
AATD Died
M; 52 Since 10 days postpartum
150 μg/day per os
Intracranial bleeding Yes BF > 200/
> 180/
NM
Unknown Epilepsy
F; 72 1 mg postpartum,
150 μg/day per os
Intracranial, nasal, and
gastro-intestinal
bleeding, hematomas
Yes BF > 150/
> 18/
NM
PFIC type 2 Died
F; 37 1 mg postpartum,
150 μg/day per os
Intracranial bleeding Yes BF 58/
39.9/
3.92*
Biliary atresia Died
M; 38 1 mg postpartum,
150 μg/day per os
Intracranial and
gastro-intestinal bleeding
Yes BF 120/
120/
NM
Unknown No sequelae
F; 21 1 mg postpartum,
150 μg/day per os
Intracranial bleeding Yes BF > 180/
> 90/
NM
Suspected PFIC Full recovery
F; 45 1 mg postpartum,
150 μg/day per os
Hematomas chest and hand No BF > 200/
> 10/
NM
Biliary atresia Full recovery
M; 19 1 mg postpartum,
150 μg/day per os
Umbilical bleeding No BF > 180/
> 180/
NM
AATD Unknown
M; 17 No administration Gastro-intestinal bleeding No BF 152/
147/
NM
None Unknown
M male, F female, BF breastfeeding, APTT activated partial thromboplastin time, PT prothrombin time, INR international normalized ratio, NM not
measured, AATD alpha-1 antitrypsin deficiency, PFIC progressive familial intrahepatic cholestasis
*Measured after vitamin K administration
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there was a significant difference between the intracranial lo-
calization of hematomas in infants with VKDB and in infants
with bleeding due to NABI: the latter group presented primar-
ily with subdural hematomas whereas VKDB predominantly
manifested as a combination of subdural and intracerebral
bleeding (p = 0.020).
Late intracranial VKDB
Under the 25-μg regimen (January 2008–February 2011;
38 months), late intracranial VKDB was confirmed in 18
infants and suspected in 2 additional infants in whom
diagnosis could not be confirmed as PT was measured
after vitamin K supplementation had been introduced.
Under the 150-μg regimen (March 2011–December
2015; 58 months), late intracranial VKDB was confirmed
in 10 infants (Table 2). Clinical and biochemical charac-
teristics of infants with confirmed late intracranial VKDB
are listed in Table 3. Under the 25-μg regimen, all in-
fants were exclusively breastfed. In all 16 infants in
which bilirubin values were available, both the total
and direct fractions were raised, suggesting suboptimal
bile flow. Of these, 14 infants met the previously de-
scribed criteria of cholestasis. An underlying disorder
predisposing to cholestasis was identified in 12 (67%)
infants: biliary atresia (6), α-1 antitrypsin deficiency (2),
progressive familial intrahepatic cholestasis (PFIC) (2),
Alagille syndrome (1), and extra hepatic biliary
obstruction (1). Four of these infants had received inad-
equate vitamin K administration.
Under the 150-μg regimen, 8 (80%) out of 10 infants had
been exclusively breastfed, and from 1 infant, the feeding type
was unknown and 1 infant received formula feeding (un-
known type). In all 10 infants, bilirubin was measured; all
had raised bilirubin values. Of these, 8 infants met the previ-
ously described criteria of cholestasis. An underlying disorder
predisposing to cholestasis was specified in 7 infants: biliary
atresia (4), α-1 antitrypsin deficiency, PFIC, and Zellweger
syndrome (1 each). Two infants had received inadequate vita-
min K administration.
Incidence of late intracranial VKDB
The annual incidence of late intracranial VKDB under the
former regimen of 25 μg vitamin K ranged from 1.6 per
100,000 live births (95% CI, 0.4–5.2) to 4.9 per 100,000 live
births (95% CI, 2.4–9.6), with an average incidence of 3.1 per
100,000 live births (95% CI, 1.9–5.0). When infants with
suspected VKDB were included in the analysis, the average
incidence was 3.4 per 100,000 live births (95% CI, 2.2–5.4).
After implementation of the 150-μg regimen, the annual inci-
dence of late intracranial VKDB ranged from 0.6 per 100,000
live births (95% CI, 0.0–3.7) to 1.8 per 100,000 live births
(95% CI, 0.5–5.6), with an average incidence of late intracra-
nial VKDB of 1.2 per 100,000 live births (95% CI, 0.6–2.3)
(Table 4).
Table 2 Causes of intracranial
bleeding in infants between the
age of 8 days and 6 months
admitted to a Dutch PICU
between 2008 and 2015 under
two different vitamin K oral
prophylactic regimens
25 μg: January
2008–February 2011
150 μg: March
2011–December 2015
Cause Number (%) Number (%) p value
Non-accidental brain injury 39 (44) 34 (39) 0.482
Vitamin K deficiency 20 (23) 10 (12) 0.041
Confirmed 18 (21) 10 (12) 0.092
Accidental head trauma 19 (22) 26 (30) 0.244
Other coagulation disorders 1 (1) 3 (3) 0.621
Iatrogenous 2 (2) 2 (2) 1.000
Unknown 1 (1) 4 (5) 0.368
Vascular malformation 1 (1) 3 (3) 0.621
Due to meningitis 1 (1) 3 (3) 0.621
Due to disseminated intravascular coagulation 2 (2) 0 (0) 0.246
Secondarily to sinus thrombosis 1 (1) 1 (1) 1.000
Birth trauma 1 (1) 0 (0) 0.497
Genetic collagen disorder 0 (0) 1 (1) 1.000
Total 88 87
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Time between events
As a consequence, the median time between consecutive
cases increased significantly after the introduction of
this regimen, from 24 under the 25-μg regimen to
154 days under the 150-μg regimen (p < 0.001).
(Fig. 1a, b).
Sensitivity analysis
When excluding infants who had received inadequate
prophylaxis (4 and 2 infants for the 25-μg and 150-μg
regimens, respectively) and infants who developed intra-
cranial VKDB due to treatment failure (1 infant for the
150-μg regimen), the adjusted incidence of late intracra-
nial VKDB under the 25-μg regimen was calculated as
2.4 per 100,000 live births (95% CI, 1.4–4.1). The ad-
justed incidence under the 150-μg regimen was calcu-
lated as 0.8 per 100,000 live births (95% CI, 0.4–1.8).
Discussion
In this study, we exploited two independent nationwide
surveillance strategies to determine the effect of a six-
fold dose increase of oral vitamin K prophylaxis on the
incidence of intracranial hemorrhages due to VKD and
showed that the incidence of late intracranial VKDB
was modestly reduced after introduction of the revised
regimen. However, the protection obtained by this six-
fold dose increase is limited in comparison with the
excellent protection offered by a single dose of IM vi-
tamin K after birth [12] and is unexpectedly lower than
a regimen previously used in Denmark with the same
cumulative weekly dose of vitamin K [23]. This dis-
crepancy strongly suggests that factors other than the
dose must play an important role. Compliance issues
with the daily regimen might contribute to poor protec-
tion; however, this was the case in only 2 infants for
the revised regimen, and previous investigations indicate
compliance is generally adequate [21]. Improved
Table 3 Comparison of
characteristics of infants with
confirmed late intracranial VKDB
admitted to a PICU in the
Netherlands under the 25-μg and
150-μg oral prophylactic
regimens
25 μg: January
2008–February 2011
150 μg: March
2011–December 2015
p value
Feature
Male/female, N (%) 9 (50)/9 (50) 8 (80)/2 (20) 0.226
Birth weight, mean (range), g 3496 (2830–4245) 3352 (2510–4000) 0.509
Age at diagnosis, mean (range), days 45 (28–97) 54 (21–101) 0.337
Weight at diagnosis, mean (range), g 4428 (3170–5500) 4681 (3400–5600) 0.358
Biochemical parameters
Bilirubin total, median (range), μmol/l 81 (26–242) 77 (45–246) 0.792
Bilirubin direct, median (range), μmol/l 44 (8–131) 59 (23–206) 0.482
ASAT, median (range), U/l 68 (20–399) 96 (40–526) 0.350
ALAT, median (range), U/l 45 (15–232) 53 (21–224) 0.415
Etiology
Exclusively breastfed, N (%) 18 (100) 8 (80) 0.150
Cholestasis, N (%) 14 (78) 8 (80) 0.625
Underlying disorder, N (%) 12 (67) 7 (70) 1.000
Inadequate administration, N (%) 4 (22) 2 (20) 1.000
Short-term outcome
MRPIM2, median (P25-P75) 0.17 (0.03–0.29) 0.06 (0.04–0.23) 0.532
Neurosurgical intervention, N (%) 7 (39) 3 (30) 0.703
Mechanical ventilation, N (%) 14 (78) 7 (70) 0.674
Duration of mechanical ventilation, median
(range), days
4 (1–13) 4 (2–12) 0.771
Length of stay at a PICU, median (range), days 4 (1–15) 5 (2–15) 0.551
Long-term outcome
Died, N (%) 5 (28) 4 (40) 0.677
Neurological sequelae, N (%) 3 (17) 2 (20) 0.635
VKDB vitamin K deficiency bleeding, PICU pediatric intensive care unit, N number, ASAT asparagine amino-
transferase, ALAT alanine aminotransferase, MRPIM2 pediatric index of mortality: mortality rate
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fractional absorption of one larger dosage compared
with multiple smaller dosages has been suggested, al-
t h o ugh ev i d e n c e i s c u r r e n t l y l a c k i n g [ 2 9 ] .
Alternatively, the formulation in which vitamin K is
administered could be an explanation. Dutch oral vita-
min K is dissolved in arachnid oil, the hydrophobic
nature of which is likely to impede absorption in infants
with suboptimal bile flow. In several countries with oral
vitamin K regimens, vitamin K is administered through
Konakion® mixed micelles (MM) which more closely
resembles the situation in the gut. However, even this
formulation does not fully prevent VKDB in infants
with cholestasis due to impaired intestinal absorption
[26], likely due to micellar decomposition in the stom-
ach as a consequence of low pH [22]. A recent study
describes a new formulation of vitamin K prophylaxis
which circumvents gastric micellar decomposition and
therefore might be a promising oral form of prophylaxis
for infants with suboptimal bile flow [19].
The present study underlines the usefulness of pedi-
atric intensive care registries in assessing the efficacy of
national regimens of vitamin K prophylaxis. First, this
study confirms that this targeted approach is associated
with higher retrieval rates as compared with general
surveillance studies [25]. Higher retrieval decreases the
risk that differences in calculated incidences are due to
variations in retrieval rate rather than changes in the
true incidence. It is important to take the higher retriev-
al rate, thus higher incidences, into account when com-
paring incidences obtained from general surveillance
with those obtained using targeted surveillance.
Second, the detailed information regarding timing of
events allowed us to calculate the time between events.
The latter made it possible to attach statistical signifi-
cance to the lower incidence of late intracranial VKDB
after the change of regimen. We expect this measure to
be helpful to assess the efficacy of upcoming prophy-
lactic regimens. Virtually, all patients who develop
VKDB despite prophylaxis have evidence of impaired
bile flow, highlighting the importance of this risk factor.
Of note, in some patients, bile flow is not completely
obstructed, and therefore they do not fulfill commonly
used criteria for cholestasis [23]. The inability of the
150-μg regimen to protect infants with cholestasis
against VKDB has led to a recent advice by the
Dutch Health Council to switch from the oral daily
150-μg regimen to a single dose of IM vitamin K pro-
phylaxis at birth [5].
There is limited recent data of incidences of late
VKDB in other countries with oral prophylactic regi-
mens; in addition, prophylactic regimens may vary with-
in countries. The lowest oral dosing regimen of 3 ×
1 mg has been accompanied by the highest incidencesTa
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of late VKDB (1.3 and 1.5 per 100,000 in Germany and
Australia, respectively, for the years 1993 and 1994).
An oral dosing regimen of 2 × 2 mg vitamin K in
Switzerland resulted in an incidence of 1.2 per
100,000 for 1995–2002. For a dosing regimen of 3 ×
2 mg, incidences varied from 0.4 to 0.8 per 100,000 in
1995–2001 (Germany), 0.43 per 100,000 (UK), and
0.87 per 100,000 since 2003 (Switzerland). The lowest
incidence of late VKDB under oral vitamin K prophy-
laxis has been described in Denmark: 0.0 per 100,000
in 1992–2000 (2 mg vitamin K at birth, followed by
1 mg weekly for 3 months). However, Denmark
switched to IM vitamin K administration in 2000 due
to a lack of a licensed product. For countries with IM
prophylaxis, lower incidences of 0.37 per 100,000
(Canada), 0.16 per 100,000 (New Zealand), and 0.1
per 100,000 (UK, 1 mg IM vitamin K at birth, 3 ×
1 mg orally) have been described [11, 12]. Based on
this superior efficacy, the NICE guidelines of 2015 rec-
ommend IM vitamin K prophylaxis for all newborns to
prevent VKDB [13].
Despite its efficacy, IM administration of vitamin K
increasingly encounters resistance from parents [9].
Reasons for concern include exposure of the baby to
toxic ingredients, excessive dose and side effects, the
fear of an, although not substantiated [7], association
with cancer, and the painful injections. Inadequate infor-
mation during the antenatal period about the importance
of vitamin K prophylaxis can also be a reason for re-
fusal: parents consider vitamin K unphysiological and
therefore gratuitous in uncomplicated birth [16, 28].
Risk factors for parental refusal of IM vitamin K ad-
ministration were previously described [9, 15]. Vitamin
K refusal was more likely to be associated with planned
home delivery and midwife-assisted deliveries than
hospital delivery and delivery by a physician. In the
Netherlands, a substantial part of newborns is delivered
at home (18.4% vs. 80.7% in a hospital vs. 0.9% else-
where) [3] and could consequently be at risk of parental
IM vitamin K refusal. Proper counseling, especially dur-
ing the antenatal period, is therefore of great impor-
tance. If parents persist and refuse to have their child
injected, the Dutch Health Council presently recom-
mends an oral alternative, namely, 3 doses of 2 mg
vitamin K (at birth, after 4–6 days and 4–6 weeks) for
breastfed infants [5], based on a Swiss study [8]. The
NICE guidelines also recommend oral vitamin K as a
second-line option in case of parental decline, although
dose and dosage frequency are not specified [13].
There are some limitations to this study. It is possible
that some cases with intracranial VKDB were not admit-
ted to the PICU in case of few symptoms, or died else-
where and therefore remained unreported. Furthermore,
earlier detection of cholestatic liver disease, including
biliary atresia, may theoretically decrease the incidence
of late VKDB, as these infants are treated with higher
vitamin K dosages once diagnosed. However, since there
has been no change in the number of registered patients
with biliary atresia or the age at diagnosis after introduc-
tion of the revised regimen [29], this is not likely to have
influenced the results. Finally, targeted surveillance with-
in relevant subpopulations requires the existence of na-
tional registries. This in turn demands a substantial and
ongoing effort, the importance of which cannot easily be
overstated.
In conclusion, a sixfold increase in the oral prophy-
lactic vitamin K dose—from 25 to 150 μg daily—
resulted in a significant but relatively modest reduction
in the incidence of late intracranial VKDB. However,
this protection compares poorly to the efficacy of IM
a bFig. 1 a Time in days between
consecutive cases of late
intracranial VKDB under the 25-
μg and 150-μg regimens. b
Cumulative cases of intracranial
VKDB under the 25-μg and 150-
μg regimens
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vitamin K prophylaxis, indicating that factors other than
the dose should be addressed to further improve oral
vitamin K prophylactic regimens.
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